Ischaemic conditioning: Pitfalls on the path to clinical translation

British Journal of Pharmacology

Volumn 172, Issue 8, 2015, Pages 1961-1973

  Przyklenk, Karin ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

G PROTEIN COUPLED RECEPTOR;

ACUTE HEART INFARCTION; AGING; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR SURGERY; CLINICAL EFFECTIVENESS; CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); COMORBIDITY; CORONARY ARTERY BYPASS GRAFT; DISEASE MODEL; HEART INFARCTION PREVENTION; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; ISCHEMIC POSTCONDITIONING; ISCHEMIC PRECONDITIONING; MEMBRANE STABILIZATION; META ANALYSIS (TOPIC); MITOCHONDRION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMOTE PRECONDITIONING; REPERFUSION INJURY; REVIEW; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STUDY DESIGN; SYSTEMATIC REVIEW (TOPIC); TIME; UPREGULATION; ANIMAL; METHODOLOGY; MYOCARDIAL REPERFUSION INJURY; TRANSLATIONAL RESEARCH;

ANIMALS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; HUMANS; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MYOCARDIAL REPERFUSION INJURY; RESEARCH DESIGN; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84925846735     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13064     Document Type: Review

References (131)

1. Abdelnoor M, Sandven I, Limalanathan S, Eritsland J, (2014). Postconditioning in ST-elevation myocardial infarction: a systematic review, critical appraisal, and meta-analysis of randomized clinical trials. Vasc Health Risk Manag 10: 477-491.
2. Abete P, Ferrara N, Cacciatore F, Madrid A, Bianco S, Calabrese C, et al. (1997). Angina-induced protection against myocardial infarction in adult and elderly patients: a loss of preconditioning mechanism in the aging heart? J Am Coll Cardiol 30: 947-954.
3. Abete P, Cacciatore F, Testa G, Della-Morte D, Galizia G, de Santis D, et al. (2010). Ischemic preconditioning in the aging heart: from bench to bedside. Ageing Res Rev 9: 153-162.
4. Adam T, Sharp S, Opie LH, Lecour S, (2013). Loss of cardioprotection with ischemic preconditioning in aging hearts: role of sirtuin 1? J Cardiovasc Pharmacol Ther 18: 46-53.
5. Albrecht M, Zitta K, Bein B, Wennemuth G, Broch O, Renner J, et al. (2013). Remote ischemic preconditioning regulates HIF-1alpha levels, apoptosis and inflammation in heart tissue of cardiosurgical patients: a pilot experimental study. Basic Res Cardiol 108: 314.
6. Alegria JR, Miller TD, Gibbons RJ, Yi QL, Yusuf S, (2007). Infarct size, ejection fraction, and mortality in diabetic patients with acute myocardial infarction treated with thrombolytic therapy. Am Heart J 154: 743-750.
7. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013a). The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors. Br J Pharmacol 170: 1459-1581.
8. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013b). The Concise Guide to PHARMACOLOGY 2013/14: Ion channels. Br J Pharmacol 170: 1607-1651.
9. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013c). The Concise Guide to PHARMACOLOGY 2013/14: Enzymes. Br J Pharmacol 170: 1797-1867.
10. Altman DG, Bland JM, (2011). How to obtain the P value from a confidence interval. BMJ 343: d2304.
11. Barja G, Herrero A, (2000). Oxidative damage to mitochondrial DNA is inversely related to maximum life span in the heart and brain of mammals. FASEB J 14: 312-318.
12. Boengler K, Konietzka I, Buechert A, Heinen Y, Garcia-Dorado D, Heusch G, et al. (2007). Loss of ischemic preconditioning's cardioprotection in aged mouse hearts is associated with reduced gap junctional and mitochondrial levels of connexin 43. Am J Physiol Heart Circ Physiol 292: H1764-H1769.
13. Boengler K, Buechert A, Heinen Y, Roeskes C, Hilfiker-Kleiner D, Heusch G, et al. (2008). Cardioprotection by ischemic postconditioning is lost in aged and STAT3-deficient mice. Circ Res 102: 131-135.
14. Boengler K, Schulz R, Heusch G, (2009). Loss of cardioprotection with ageing. Cardiovasc Res 83: 247-261.
15. Bolli R, (2000). The late phase of preconditioning. Circ Res 87: 972-983.
16. Botker HE, Kharbanda R, Schmidt MR, Bottcher M, Kaltoft AK, Terkelsen CJ, et al. (2010). Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial. Lancet 375: 727-734.
17. Bouhidel O, Pons S, Souktani R, Zini R, Berdeaux A, Ghaleh B, (2008). Myocardial ischemic postconditioning against ischemia-reperfusion is impaired in ob/ob mice. Am J Physiol Heart Circ Physiol 295: H1580-H1586.
18. Braunwald E, Kloner RA, (1985). Myocardial reperfusion: a double-edged sword? J Clin Invest 76: 1713-1719.
19. Burns PG, Krunkenkamp IB, Calderone CA, Kirvaitis RJ, Gaudette GR, Levitsky S, (1996). Is the preconditioning response conserved in senescent myocardium? Ann Thorac Surg 61: 925-929.
20. Carrasco-Chinchilla F, Munoz-Garcia AJ, Dominguez-Franco A, Millan-Vazquez G, Guerrero-Molina A, Ortiz-Garcia C, et al. (2013). Remote ischaemic postconditioning: does it protect against ischaemic damage in percutaneous coronary revascularisation? Randomised placebo-controlled clinical trial. Heart 99: 1431-1437.
21. Cohen MV, Downey JM, (2011). Is it time to translate ischemic preconditioning's mechanism of cardioprotection into clinical practice? J Cardiovasc Pharmacol Ther 16: 273-280.
22. Cohen MV, Downey JM, (2015). Signaling pathways and mechanisms of protection in pre- and postconditioning: historical perspective and lessons for the future. Br J Pharmacol. doi: 10.1111/bph.12903. [Epub ahead of print: Sept 10 2014.]
23. Dai W, Simkhovich BZ, Kloner RA, (2009). Ischemic preconditioning maintains cardioprotection in aging normotensive and spontaneously hypertensive rats. Exp Gerontol 44: 344-349.
24. Darling CE, Solari PB, Smith CS, Furman MI, Przyklenk K, (2007). Postconditioning' the human heart: multiple balloon inflations during primary angioplasty may confer cardioprotection. Basic Res Cardiol 102: 274-278.
25. Davies WR, Brown AJ, Watson W, McCormick LM, West NE, Dutka DP, et al. (2013). Remote ischemic preconditioning improves outcome at 6 years after elective percutaneous coronary intervention: the CRISP stent trial long-term follow-up. Circ Cardiovasc Interv 6: 246-251.
26. D'Ascenzo F, Moretti C, Omede P, Cerrato E, Cavallero E, Er F, et al. (2014). Cardiac remote ischaemic preconditioning reduces periprocedural myocardial infarction for patients undergoing percutaneous coronary interventions: a meta-analysis of randomised clinical trials. EuroIntervention 9: 1463-1471.
27. Dickson EW, Blehar DJ, Carraway RE, Heard SO, Steinberg G, Przyklenk K, (2001). Naloxone blocks transferred preconditioning in isolated rabbit hearts. J Mol Cell Cardiol 33: 1751-1756.
28. Donato M, Buchholz B, Rodriguez M, Perez V, Inserte J, Garcia-Dorado D, et al. (2013). Role of the parasympathetic nervous system in cardioprotection by remote hindlimb ischaemic preconditioning. Exp Physiol 98: 425-434.
29. Dow J, Kloner RA, (2007). Postconditioning does not reduce myocardial infarct size in an in vivo regional ischemia rodent model. J Cardiovasc Pharmacol Ther 12: 153-163.
30. Ebrahim Z, Yellon DM, Baxter GF, (2007). Ischemic preconditioning is lost in aging hypertensive rat heart: independent effects of aging and longstanding hypertension. Exp Gerontol 42: 807-814.
31. Fenton RA, Dickson EW, Meyer TE, Dobson JG Jr, (2000). Aging reduces the cardioprotective effect of ischemic preconditioning in the rat heart. J Mol Cell Cardiol 32: 1371-1375.
32. Ferdinandy P, Schulz R, Baxter GF, (2007). Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacol Rev 59: 418-458.
33. Ferdinandy P, Hausenloy DJ, Heusch G, Baxter GF, Schulz R, (2014). Interaction of risk factors, comorbidities, and comedications with ischemia/reperfusion injury and cardioprotection by preconditioning, postconditioning, and remote conditioning. Pharmacol Rev 66: 1142-1174.
34. Freixa X, Bellera N, Ortiz-Perez JT, Jimenez M, Pare C, Bosch X, et al. (2012). Ischaemic postconditioning revisited: lack of effects on infarct size following primary percutaneous coronary intervention. Eur Heart J 33: 103-112.
35. Garcia S, Henry TD, Wang YL, Chavez IJ, Pedersen WR, Lesser JR, et al. (2011). Long-term follow-up of patients undergoing postconditioning during ST-elevation myocardial infarction. J Cardiovasc Transl Res 4: 92-98.
36. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al. (2014). Heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation 129: e28-e292.
37. Gourine A, Gourine AV, (2014). Neural mechanisms of cardioprotection. Physiology (Bethesda) 29: 133-140.
38. Gregg EW, Zhuo X, Cheng YL, Albright AL, Narayan KMV, Thompson TJ, (2014). Trends in lifetime risk and years of life lost due to diabetes in the USA, 1985-2011: a modelling study. Lancet Diabetes Endocrinol 14: 70161-70165.
39. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M, (1998). Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339: 229-234.
40. Hahn JY, Song YB, Kim EK, Yu CW, Bae JW, Chung WY, et al. (2013). Ischemic postconditioning during primary percutaneous coronary intervention: the effects of postconditioning on myocardial reperfusion in patients with ST-segment elevation myocardial infarction (POST) randomized trial. Circulation 128: 1889-1896.
41. Hausenloy DJ, Yellon DM, (2009). Preconditioning and postconditioning: underlying mechanisms and clinical application. Atherosclerosis 204: 334-341.
42. Hausenloy DJ, Lecour S, Yellon DM, (2011a). Reperfusion injury salvage kinase and survivor activating factor enhancement prosurvival signaling pathways in ischemic postconditioning: two sides of the same coin. Antioxid Redox Signal 14: 893-907.
43. Hausenloy DJ, Candilio L, Laing C, Kunst G, Pepper J, Kolvekar S, et al. (2011b). Effect of remote ischemic preconditioning on clinical outcomes in patients undergoing coronary artery bypass graft surgery (ERICCA): rationale and study design of a multi-centre randomized double-blinded controlled clinical trial. Clin Res Cardiol 101: 339-348.
44. Hausenloy DJ, Wynne AM, Mocanu MM, Yellon DM, (2013a). Glimepiride treatment facilitates ischemic preconditioning in the diabetic heart. J Cardiovasc Pharmacol Ther 18: 263-269.
45. Hausenloy DJ, Botker EH, Condorelli G, Ferdinandy P, Garcia-Dorado D, Heusch G, et al. (2013b). Translating cardioprotection for patient benefit: position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. Cardiovasc Res 98: 7-27.
46. Healy DA, Khan WA, Wong CS, Moloney MC, Grace PA, Coffey JC, et al. (2014). Remote preconditioning and major clinical complications following adult cardiovascular surgery: systematic review and meta-analysis. Int J Cardiol 176: 20-31.
47. Heusch G, (2013). Cardioprotection: chances and challenges of its translation to the clinic. Lancet 381: 166-175.
48. Heusch G, Boengler K, Schulz R, (2008). Cardioprotection: nitric oxide, protein kinases, and mitochondria. Circulation 118: 1915-1919.
49. Higgins JP, Thompson SG, Deeks JJ, Altman DG, (2003). Measuring inconsistency in meta-analyses. BMJ 327: 557-560.
50. Hoole SP, Heck PM, Sharples L, Khan SN, Duehmke R, Densem CG, et al. (2009). Cardiac Remote Ischemic Preconditioning in Coronary Stenting (CRISP Stent) Study: a prospective, randomized control trial. Circulation 119: 820-827.
51. Huffmyer J, Raphael J, (2009). Physiology and pharmacology of myocardial preconditioning and postconditioning. Semin Cardiothorac Vasc Anesth 13: 5-18.
52. Iliodromitis EK, Kyrzopoulos S, Paraskevaidis IA, Kolocassides KG, Adamopoulos S, Karavolias G, et al. (2006). Increased C reactive protein and cardiac enzyme levels after coronary stent implantation. Is there protection by remote ischaemic preconditioning? Heart 92: 1821-1826.
53. Ishihara M, Inoue I, Kawagoe T, Shimatani Y, Kurisu S, Nishioka K, et al. (2001). Diabetes mellitus prevents ischemic preconditioning in patients with a first acute anterior wall myocardial infarction. J Am Coll Cardiol 38: 1007-1011.
54. Jimenez-Navarro M, Gomez-Doblas JJ, Alonso-Briales J, Hernandez Garcia JM, Gomez G, Alcantara AG, et al. (2001). Does angina the week before protect against first myocardial infarction in elderly patients? Am J Cardiol 87: 11-15.
55. Kanoria S, Jalan R, Seifalian AM, Williams R, Davidson BR, (2007). Protocols and mechanisms for remote ischemic preconditioning: a novel method for reducing ischemia reperfusion injury. Transplantation 84: 445-458.
56. Katakam PV, Jordan JE, Snipes JA, Tulbert CD, Miller AW, Busija DW, (2007). Myocardial preconditioning against ischemia-reperfusion injury is abolished in Zucker obese rats with insulin resistance. Am J Physiol Regul Integr Comp Physiol 292: R920-R926.
57. Kharbanda RK, Mortensen UM, White PA, Kristiansen SB, Schmidt MR, Hoschtitzky JA, et al. (2002). Transient limb ischemia induces remote ischemic preconditioning in vivo. Circulation 106: 2881-2883.
58. Kin H, Zhao ZQ, Sun HY, Wang NP, Corvera JS, Halkos ME, et al. (2004). Postconditioning attenuates myocardial ischemia-reperfusion injury by inhibiting events in the early minutes of reperfusion. Cardiovasc Res 62: 74-85.
59. Kleinbongard P, Heusch G, (2015). Extracellular signaling molecules in the ischaemic/reperfused heart-druggable and translatable for cardioprotection? Br J Pharmacol. doi: 10.1111/bph.12902. [Epub ahead of print: Sept 10 2014].
60. Kloner RA, Przyklenk K, Shook T, Cannon CP, (1998). Protection conferred by preinfarct angina is manifest in the aged heart: evidence from the TIMI 4 trial. J Thromb Thrombolysis 6: 89-92.
61. Kottenberg E, Thielmann M, Bergmann L, Heine T, Jakob H, Heusch G, et al. (2012). Protection by remote ischemic preconditioning during coronary artery bypass graft surgery with isoflurane but not propofol-a clinical trial. Acta Anaesthesiol Scand 56: 30-38.
62. Kottenberg E, Musiolik J, Thielmann M, Jakob H, Peters J, Heusch G, (2014). Interference of propofol with signal transducer and activator of transcription 5 activation and cardioprotection by remote ischemic preconditioning during coronary artery bypass grafting. J Thorac Cardiovasc Surg 147: 376-382.
63. Krempf M, Parhofer KG, Steg PG, Bhatt DL, Ohman EM, Rother J, et al. (2010). Cardiovascular event rates in diabetic and nondiabetic individuals with and without established atherothrombosis (from the REduction of the rothrombosis for Continued Health [REACH] Registry). Am J Cardiol 105: 667-671.
64. Kristiansen SB, Lofgren B, Stottrup NB, Khatir D, Nielsen-Kudsk JE, Nielsen TT, et al. (2004). Ischaemic preconditioning does not protect the heart in obese and lean animal models of type 2 diabetes. Diabetologia 47: 1716-1721.
65. Laskey WK, Yoon S, Calzada N, Ricciardi MJ, (2008). Concordant improvements in coronary flow reserve and ST-segment resolution during percutaneous coronary intervention for acute myocardial infarction: a benefit of postconditioning. Catheter Cardiovasc Interv 72: 212-220.
66. Lefer DJ, Bolli R, (2011). Development of an NIH consortium for preclinicAl AssESsment of CARdioprotective therapies (CAESAR): a paradigm shift in studies of infarct size limitation. J Cardiovasc Pharmacol Ther 16: 332-339.
67. Lim SY, Yellon DM, Hausenloy DJ, (2010). The neural and humoral pathways in remote limb ischemic preconditioning. Basic Res Cardiol 105: 651-655.
68. Limalanathan S, Andersen GO, Klow NE, Abdelnoor M, Hoffmann P, Eritsland J, (2014). Effect of ischemic postconditioning on infarct size in patients with ST-elevation myocardial infarction treated by primary PCI results of the POSTEMI (POstconditioning in ST-Elevation Myocardial Infarction) randomized trial. J Am Heart Assoc 3: e000679.
69. Longacre LS, Kloner RA, Arai AE, Baines CP, Bolli R, Braunwald E, et al. (2011). New horizons in cardioprotection recommendations from the 2010 national heart, lung, and blood institute workshop. Circulation 124: 1172-1179.
70. Mastitskaya S, Marina N, Gourine A, Gilbey MP, Spyer KM, Teschemacher AG, et al. (2012). Cardioprotection evoked by remote ischaemic preconditioning is critically dependent on the activity of vagal pre-ganglionic neurones. Cardiovasc Res 95: 487-494.
71. Meybohm P, Zacharowski K, Cremer J, Roesner J, Kletzin F, Schaelte G, et al. (2012). Remote ischaemic preconditioning for heart surgery. The study design for a multi-center randomized double-blinded controlled clinical trial-the RIPHeart-Study. Eur Heart J 33: 1423-1426.
72. Miki T, Itoh T, Sunaga D, Miura T, (2012). Effects of diabetes on myocardial infarct size and cardioprotection by preconditioning and postconditioning. Cardiovasc Diabetol 11: 67.
73. Murcia AM, Hennekens CH, Lamas GA, Jimenez-Navarro M, Rouleau JL, Flaker GC, et al. (2004). Impact of diabetes on mortality in patients with myocardial infarction and left ventricular dysfunction. Arch Intern Med 164: 2273-2279.
74. Murphy E, Steenbergen C, (2008). Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury. Physiol Rev 88: 581-609.
75. Murry CE, Jennings RB, Reimer KA, (1986). Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 74: 1124-1136.
76. Nakano A, Heusch G, Cohen MV, Downey JM, (2002). Preconditioning one myocardial region does not necessarily precondition the whole rabbit heart. Basic Res Cardiol 97: 35-39.
77. Nichols M, Townsend N, Scarborough P, Rayner M, (2013). Cardiovascular disease in Europe: epidemiological update. Eur Heart J 34: 3028-3034.
78. Okamoto F, Allen BS, Buckberg GD, Bugyi H, Leaf J, (1986). Reperfusion conditions: importance of ensuring gentle versus sudden reperfusion during relief of coronary occlusion. J Thorac Cardiovasc Surg 92 (3 Pt 2): 613-620.
79. Oosterlinck W, Dresselaers T, Geldhof V, Nevelsteen I, Janssens S, Himmelreich U, et al. (2013). Diabetes mellitus and the metabolic syndrome do not abolish, but might reduce, the cardioprotective effect of ischemic postconditioning. J Thorac Cardiovasc Surg 145: 1595-1602.
80. Ovize M, Baxter GF, Di Lisa F, Ferdinandy P, Garcia-Dorado D, Hausenloy DJ, et al. (2010). Postconditioning and protection from reperfusion injury: where do we stand? Position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. Cardiovasc Res 87: 406-423.
81. Ovize M, Thibault H, Przyklenk K, (2013). Myocardial conditioning: opportunities for clinical translation. Circ Res 113: 439-450.
82. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al.; NC-IUPHAR (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucleic Acids Res 42 (Database Issue): D1098-D1106.
83. Przyklenk K, (2011). Efficacy of cardioprotective 'conditioning' strategies in aging and diabetic cohorts: the co-morbidity conundrum. Drugs Aging 28: 331-343.
84. Przyklenk K, (2013). Reduction of myocardial infarct size with ischemic 'conditioning': physiologic and technical considerations. Anesth Analg 117: 891-901.
85. Przyklenk K, Whittaker P, (2011). Remote ischemic preconditioning: current knowledge, unresolved questions, and future priorities. J Cardiovasc Pharmacol Ther 16: 255-259.
86. Przyklenk K, Whittaker P, (2013). Genesis of remote conditioning: action at a distance-'hypotheses non fingo. J Cardiovasc Med (Hagerstown) 14: 180-186.
87. Przyklenk K, Bauer B, Ovize M, Kloner RA, Whittaker P, (1993). Regional ischemic 'preconditioning' protects remote virgin myocardium from subsequent sustained coronary occlusion. Circulation 87: 893-899.
88. Przyklenk K, Li G, Whittaker P, (2001). No loss in the in vivo efficacy of ischemic preconditioning in middle-aged and old rabbits. J Am Coll Cardiol 38: 1741-1747.
89. Przyklenk K, Li G, Simkhovich BZ, Kloner RA, (2003). Mechanisms of myocardial ischemic preconditioning are age related: PKC-epsilon does not play a requisite role in old rabbits. J Appl Physiol 95: 2563-2569.
90. Przyklenk K, Maynard M, Darling CE, Whittaker P, (2008). Aging mouse hearts are refractory to infarct size reduction with post-conditioning. J Am Coll Cardiol 51: 1393-1398.
91. Przyklenk K, Maynard M, Greiner DL, Whittaker P, (2011). Cardioprotection with postconditioning: loss of efficacy in murine models of type-2 and type-1 diabetes. Antioxid Redox Signal 14: 781-790.
92. Rahman IA, Mascaro JG, Steeds RP, Frenneaux MP, Nightingale P, Gosling P, et al. (2010). Remote ischemic preconditioning in human coronary artery bypass surgery: from promise to disappointment? Circulation 122 (11 Suppl.): S53-S59.
93. Redington KL, Disenhouse T, Strantzas SC, Gladstone R, Wei C, Tropak MB, et al. (2012). Remote cardioprotection by direct peripheral nerve stimulation and topical capsaicin is mediated by circulating humoral factors. Basic Res Cardiol 107: 241.
94. Reimer KA, Jennings RB, (1979). The 'wavefront phenomenon' of myocardial ischemic cell death. II. Transmural progression of necrosis within the framework of ischemic bed size (myocardium at risk) and collateral flow. Lab Invest 40: 633-644.
95. Reimer KA, Lowe JE, Rasmussen MM, Jennings RB, (1977). The wavefront phenomenon of ischemic cell death. 1. Myocardial infarct size vs duration of coronary occlusion in dogs. Circulation 56: 786-794.
96. Roubille F, Mewton N, Elbaz M, Roth O, Prunier F, Cung TT, et al. (2014). No post-conditioning in the human heart with thrombolysis in myocardial infarction flow 2-3 on admission. Eur Heart J 35: 1675-1682.
97. Sachdeva J, Dai W, Gerczuk PZ, Kloner RA, (2014). Combined remote perconditioning and postconditioning failed to attenuate infarct size and contractile dysfunction in a rat model of coronary artery occlusion. J Cardiovasc Pharmacol Ther 19: 567-573.
98. Sanada S, Komuro I, Kitakaze M, (2011). Pathophysiology of myocardial reperfusion injury: preconditioning, postconditioning, and translational aspects of protective measures. Am J Physiol Heart Circ Physiol 301: H1723-H1741.
99. Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, et al. (2010). Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 375: 2215-2222.
100. Saxena P, Newman MA, Shehatha JS, Redington AN, Konstantinov IE, (2010). Remote ischemic conditioning: evolution of the concept, mechanisms, and clinical application. J Card Surg 25: 127-134.
101. Schevchuck A, Laskey WK, (2013). Ischemic conditioning as an adjunct to percutaneous coronary intervention. Circ Cardiovasc Interv 6: 484-492.
102. Schmidt MR, Redington A, Botker HE, (2015). Remote conditioning the heart overview-translatability and mechanism. Br J Pharmacol. doi: 10.1111/bph.12933. [Epub ahead of print: Sept 14 2014].
103. Schulman D, Latchman DS, Yellon DM, (2001). Effect of aging on the ability of preconditioning to protect rat hearts from ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 281: H1630-H1636.
104. Schwartz LM, Lagranha CJ, (2006). Ischemic postconditioning during reperfusion activates Akt and ERK without protecting against lethal myocardial ischemia-reperfusion injury in pigs. Am J Physiol Heart Circ Physiol 290: H1011-H1018.
105. Serejo FC, Rodrigues LF Jr, da Silva Tavares KC, de Carvalho AC, Nascimento JH, (2007). Cardioprotective properties of humoral factors released from rat hearts subject to ischemic preconditioning. J Cardiovasc Pharmacol 49: 214-220.
106. Shimizu M, Tropak M, Diaz RJ, Suto F, Surendra H, Kuzmin E, et al. (2009). Transient limb ischaemia remotely preconditions through a humoral mechanism acting directly on the myocardium: evidence suggesting cross-species protection. Clin Sci (Lond) 117: 191-200.
107. Sloth AD, Schmidt MR, Munk K, Kharbanda RK, Redington AN, Schmidt M, et al. (2014). Improved long-term clinical outcomes in patients with ST-elevation myocardial infarction undergoing remote ischaemic conditioning as an adjunct to primary percutaneous coronary intervention. Eur Heart J 35: 168-175.
108. Staat P, Rioufol G, Piot C, Cottin Y, Cung TT, L'Huillier I, et al. (2005). Postconditioning the human heart. Circulation 112: 2143-2148.
109. Steensrud T, Li J, Dai X, Manlhiot C, Kharbanda RK, Tropak M, et al. (2010). Pretreatment with the nitric oxide donor SNAP or nerve transection blocks humoral preconditioning by remote limb ischemia or intra-arterial adenosine. Am J Physiol Heart Circ Physiol 299: H1598-H1603.
110. Thibault H, Piot C, Staat P, Bontemps L, Sportouch C, Rioufol G, et al. (2008). Long-term benefit of postconditioning. Circulation 117: 1037-1044.
111. Thielmann M, Kottenberg E, Boengler K, Raffelsieper C, Neuhaeuser M, Peters J, et al. (2010). Remote ischemic preconditioning reduces myocardial injury after coronary artery bypass surgery with crystalloid cardioplegic arrest. Basic Res Cardiol 105: 657-664.
112. Thielmann M, Kottenberg E, Kleinbongard P, Wendt D, Gedik N, Pasa S, et al. (2013). Cardioprotective and prognostic effects of remote ischaemic preconditioning in patients undergoing coronary artery bypass surgery: a single-centre randomised, double-blind, controlled trial. Lancet 382: 597-604.
113. Thuny F, Lairez O, Roubille F, Mewton N, Rioufol G, Sportouch C, et al. (2012). Post-conditioning reduces infarct size and edema in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol 59: 2175-2181.
114. Tsang A, Hausenloy DJ, Mocanu MM, Carr RD, Yellon DM, (2005). Preconditioning the diabetic heart: the importance of Akt phosphorylation. Diabetes 54: 2360-2364.
115. Vinten-Johansen J, Shi W, (2011a). Perconditioning and postconditioning: current knowledge, knowledge gaps, barriers to adoption, and future directions. J Cardiovasc Pharmacol Ther 16: 260-266.
116. Vinten-Johansen J, Granfeldt A, Mykytenko J, Undyala VV, Dong Y, Przyklenk K, (2011b). The multidimensional physiological responses to postconditioning. Antioxid Redox Signal 14: 791-810.
117. Wagner C, Kloeting I, Strasser RH, Weinbrenner C, (2008). Cardioprotection by postconditioning is lost in WOKW rats with metabolic syndrome: role of glycogen synthase kinase 3beta. J Cardiovasc Pharmacol 52: 430-437.
118. Whiting DR, Guariguata L, Weil C, Shaw J, (2011). IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 94: 311-321.
119. Whittaker P, Przyklenk K, (2014). From ischemic conditioning to 'hyperconditioning': clinical phenomenon and basic science opportunity. Dose Response 12: 650-663.
120. Whittington HJ, Harding I, Stephenson CI, Bell R, Hausenloy DJ, Mocanu MM, et al. (2013). Cardioprotection in the aging, diabetic heart: the loss of protective Akt signalling. Cardiovasc Res 99: 694-704.
121. Wider J, Przyklenk K, (2014). Ischemic conditioning: the challenge of protecting the diabetic heart. Cardiovasc Diagn Ther 4: 383-396.
122. Wu ZK, Pehkonen E, Laurikka J, Kaukinen L, Honkonen EL, Kaukinen S, et al. (2001). The protective effects of preconditioning decline in aged patients undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg 122: 972-978.
123. Xue F, Yang X, Zhang B, Zhao C, Song J, Jiang T, et al. (2010). Postconditioning the human heart in percutaneous coronary intervention. Clin Cardiol 33: 439-444.
124. Yellon DM, Hausenloy DJ, (2007). Myocardial reperfusion injury. N Engl J Med 357: 1121-1135.
125. Yetgin T, Magro M, Manintveld OC, Nauta ST, Cheng JM, den Uil CA, et al. (2014). Impact of multiple balloon inflations during primary percutaneous coronary intervention on infarct size and long-term clinical outcomes in ST-segment elevation myocardial infarction: real-world postconditioning. Basic Res Cardiol 109: 403.
126. Yin Z, Gao H, Wang H, Li L, Di C, Luan R, et al. (2009). Ischaemic post-conditioning protects both adult and aged Sprague-Dawley rat heart from ischaemia-reperfusion injury through the phosphatidylinositol 3-kinase-AKT and glycogen synthase kinase-3beta pathways. Clin Exp Pharmacol Physiol 36: 756-763.
127. Young PJ, Dalley P, Garden A, Horrocks C, La Flamme A, Mahon B, et al. (2012). A pilot study investigating the effects of remote ischemic preconditioning in high-risk cardiac surgery using a randomised controlled double-blind protocol. Basic Res Cardiol 107: 256.
128. Zaugg M, Lucchinetti E, Behmanesh S, Clanachan AS, (2014). Anesthetic cardioprotection in clinical practice from proof-of-concept to clinical applications. Curr Pharm Des 20: 5706-5726.
129. Zhao ZQ, Corvera JS, Halkos ME, Kerendi F, Wang NP, Guyton RA, et al. (2003). Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol 285: H579-H588.
130. Zhu J, Rebecchi MJ, Glass PS, Brink PR, Liu L, (2013). Interactions of GSK-3beta with mitochondrial permeability transition pore modulators during preconditioning: age-associated differences. J Gerontol A Biol Sci Med Sci 68: 395-403.
131. Zhu SG, Xi L, Kukreja RC, (2012). Type 2 diabetic obese db/db mice are refractory to myocardial ischaemic post-conditioning in vivo: potential role for Hsp20, F1-ATPase delta and Echs1. J Cell Mol Med 16: 950-958.